Onco Wiki / Red flag

Low-grade glioma patient with frailty: age ≥75 with ≥2 comorbidities + albumin <3.5 g/dL,...

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Red Flag Origin

Trigger Logic

{
  "all_of": [
    {
      "any_of": [
        {
          "comparator": ">=",
          "finding": "age_years",
          "threshold": 75
        },
        {
          "comparator": ">=",
          "finding": "ecog",
          "threshold": 3
        },
        {
          "comparator": "<",
          "finding": "karnofsky_performance_status",
          "threshold": 60
        }
      ]
    },
    {
      "any_of": [
        {
          "comparator": ">=",
          "finding": "comorbidity_count",
          "threshold": 2
        },
        {
          "comparator": "<",
          "finding": "albumin_g_dl",
          "threshold": 3.5
        }
      ]
    }
  ],
  "type": "composite"
}

Notes

Per NCCN-CNS LGG section + EANO 2024 glioma frailty considerations: RT + PCV (procarbazine, lomustine, vincristine) is most efficacious in fit IDH-mut LGG (RTOG 9802) but myelosuppressive and lengthy. Frailty steers toward RT alone (54 Gy/30 fx) or TMZ-only or observation in IDH-mut low-risk variants. STUB — requires clinical co-lead signoff. NOTE: EANO-GBM is the closest in-repo source for glioma frailty; a dedicated EANO-LGG source would be a follow-up ingestion.

Used By

Indications

• IND-GLIOMA-LOW-GRADE-1L-RT-PCV - IND-GLIOMA-LOW-GRADE-1L-RT-PCV